Molecular Immunology Group

(2020)

1. Mastellos DC, Skendros P, Calado RT, Risitano AM, Lambris JD. Efficacy matters: broadening complement inhibition in COVID-19. Lancet Rheumatology Published: December 14, 2020 DOI:https://doi.org/10.1016/S2665-9913(20)30423-9 [PubMed]

​

2. Kim BJ, Mastellos DC, Li Y, Dunaief JL, Lambris JD. Targeting complement components C3 and C5 for the retina: Key concepts and lingering questions. Prog Retin Eye Res. 2020 Dec 13:100936. doi: 10.1016/j.preteyeres.2020.100936 [PubMed]

​

3. Mastellos DC, Lambris JD. Response to "Comment on Mastellos and colleagues and efficacy of complement-targeting drugs in COVID-19". Clin Immunol. 2020 Oct 25:108617. doi: 10.1016/j.clim.2020.108617 [PubMed]

​

4. Mastellos DC, Pires da Silva BGP, Fonseca BAL, Fonseca NP, Martins MA, Mastaglio S, Ruggeri A, Sironi M, Radermacher P, Chrysanthopoulou A, Skendros P, Ritis K, Manfra I, Iacobelli S, Huber-Lang M, Nilsson B, Yancopoulou D, Connolly ES, Garlanda C, Ciceri F, Risitano AM, Calado RT, Lambris JD. Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy. Clin Immunol. 2020 Sep 19:108598. doi: 10.1016/j.clim.2020.108598 [PubMed]

​

5. Skendros P, Mitsios A, Chrysanthopoulou A, Mastellos DC, Metallidis S, Rafailidis P, Ntinopoulou M, Sertaridou E, Tsironidou V, Tsigalou C, Tektonidou M, Konstantinidis T, Papagoras C, Mitroulis I, Germanidis G, Lambris JD, Ritis K. Complement and tissue factor-enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis. J Clin Invest, 2020 Aug 6:141374. doi: 10.1172/JCI141374 [PubMed]

​

6. Mastaglio S, Ruggeri A, Risitano AM, Angelillo P, Yancopoulou D, Mastellos DC, Huber-Lang M, Piemontese S, Assanelli A, Garlanda C, Lambris JD, Ciceri F. The first case of COVID-19 treated with the complement C3 inhibitor AMY-101. Clin Immunol. 2020 Apr 29:108450. doi: 10.1016/j.clim.2020.108450. [PubMed]

​

7. Risitano AM, Mastellos DC, Huber-Lang M, Yancopoulou D, Garlanda C, Ciceri F, Lambris JD. Complement as a target in COVID-19? Nat Rev Immunol. 2020 Apr 23:1-2. doi: 10.1038/s41577-020-0320-7. [PubMed]

​

8. Hughes S, Gumas J, Lee R, Rumano M, Berger N, Gautam AK, Sfyroera G, Chan AL, Gnanaguru G, Connor KM, Kim BJ, Dunaief JL, Ricklin D, Hajishengallis G, Yancopoulou D, Reis ES, Mastellos DC§, Lambris JD§. Prolonged intraocular residence and retinal tissue distribution of a fourth-generation compstatin-based C3 inhibitor in non-human primates. Clin Immunol. 2020 Mar 27;214:108391. doi: 10.1016/j.clim.2020.108391. [PubMed]

​

9. Mastellos DC§, Reis ES, Lambris JD§. Editorial: Therapeutic Modulation of the Complement System: Clinical Indications and Emerging Drug Leads. Front Immunol. 2020 Jan 9;10:3029. doi: 10.3389/fimmu.2019.03029. eCollection 2019. [PubMed]

​

(2019)

10. Ricklin D, Mastellos DC, Lambris JD. Therapeutic targeting of the complement system. Nat Rev Drug Discov. 2019 Dec 9. doi: 10.1038/s41573-019-0055-y. [PubMed]

​

11. Mastellos DC, Blom AM, Connolly ES, Daha MR, Geisbrecht BV, Ghebrehiwet B, Gros P, Hajishengallis G, Holers VM, Huber-Lang M, Kinoshita T, Mollnes TE, Montgomery RA, Morgan BP, Nilsson B, Pio R, Ricklin D, Risitano AM, Taylor RP, Mantovani A, Ioannidis JPA, Lambris JD. 'Stealth' corporate innovation: an emerging threat for therapeutic drug development. Nat Immunol. 2019 Sep 27. doi: 10.1038/s41590-019-0503-1 [PubMed]

​

12. Mastellos D.C., Ricklin D., Lambris J.D. Clinical promise of next-generation complement therapeutics. Nat Rev Drug Discov. 2019 Sep;18(9):707-729. doi: 10.1038/s41573-019-0031-6. [PubMed]

​

13. Reis E.S., Mastellos D.C., Hajishengallis G., Lambris J.D. New Insights into the Immune Functions of Complement Nat Rev Immunol 2019, 19(8):503-516. [PubMed]

​

14. K. Tsougeni, A.S. Kastania, G.D. Kaprou, Michael Eck, Gerhard Jobst, P.S. Petrou, S.E. Kakabakos, D. Mastellos, E. Gogolides, A. Tserepi. A Modular Integrated Lab-On-a-Chip platform for Fast and Highly Efficient Sample Preparation for Foodborne Pathogen Screening Sensors & Actuators: B. Chemical  Vol. 288, 1 June 2019, Pages 171-179 [Journal website]

​

15. Hajishengallis G, Kajikawa T, Hajishengallis E, Maekawa T, Reis ES, Mastellos DC, Yancopoulou D, Hasturk H and Lambris JD.. Complement-dependent mechanisms and interventions in periodontal disease. Front Immunol. 2019 Mar 12;10:406. doi: 10.3389/fimmu.2019.00406. [PubMed]

​

16. Gavriilaki E, Anagnostopoulos A, Mastellos D.C. Complement-mediated thrombotic microangiopathies: unraveling Ariadne's thread into the labyrinth of complement therapeutics Front Immunol. 2019 Feb 27;10:337. doi: 10.3389/fimmu.2019.00337. [PubMed]

​

17. Mastellos D.C., Reis ES, Biglarnia AR, Waldman M, Quigg RJ,  Huber-Lang M, Seelen MA, Daha MR, Lambris JD. Taming hemodialysis-induced inflammation: Are complement C3 inhibitors a viable option? Clin Immunol 2019 Jan;198:102-105 [PubMed]

​

(2018)

18. Mastellos DC, Reis ES, Lambris JD. Complement C5a-Mediated TAMing of Antitumor Immunity Drives Squamous Carcinogenesis. Cancer Cell. 2018 Oct 8;34(4):531-533. doi: 10.1016/j.ccell.2018.09.005. [PubMed]

​

19. Reis ES, Berger N, Wang X, Koutsogiannaki S, Doot RK, Gumas JT, Foukas PG, Resuello RRG, Tuplano JV, Kukis D, Tarantal AF, Young AJ, Kajikawa T, Soulika A, Mastellos DC, Yancopoulou D, Biglarnia AR, Huber-Lang M, Hajishengallis G, Nilsson B, Lambris JD. Safety profile after prolonged C3 inhibition. Clin Immunol, 2018 Sep 11. pii: S1521-6616(18)30559-X. doi: 10.1016/j.clim.2018.09.004 [PubMed]

​

20. Mastellos D.C., Reis ES, Yancopoulou D, Risitano AM, Lambris JD. Expanding complement therapeutics for the treatment of paroxysmal nocturnal hemoglobinuria. Semin Hematol, 2018 Jul;55(3):167-175 [PubMed]

​

21. Ricklin D, Mastellos DC, Reis ES, Lambris JD. The renaissance of complement therapeutics. Nat Rev Nephrol. 2018 Jan;14(1):26-47. [PubMed]

​

(2017)

22. Hajishengallis G, Reis ES, Mastellos DC, Ricklin D, Lambris JD. Novel mechanisms and functions of complement. Nat Immunol. 2017 Nov 16;18(12):1288-1298 [PubMed]

​

23. E.S. Reis*, D.C. Mastellos*, D. Ricklin and J.D. Lambris. Complement in cancer: untangling an intricate relationship. Nature Reviews Immunology, 2017 [PubMed]

​

24. D.C. Mastellos, E.S. Reis, D. Ricklin, R. J. Smith, and J.D. Lambris. Complement C3-targeted therapy: Replacing long-held assertions with evidence-based discovery. Trends Immunol, 2017 Jun;38(6):383-394. doi: 10.1016/j.it.2017.03.003.  [PubMed]

​

(2016)

25. Ricklin D, Reis ES, Mastellos D.C., Gros P, Lambris JD. Complement Component C3 – the “Swiss Army Knife” of Innate Immunity and Host Defense. Immunol. Reviews, 2016, 274(1):33-58. doi: 10.1111/imr.12500. [PubMed]

​

26. Mastellos D.C., Reis ES, Yancopoulou D, Hajishengallis G, Ricklin D, Lambris JD. From orphan drugs to adopted therapies: Advancing C3-targeted intervention to the clinical stage. Immunobiology. 2016 Jun 16. pii: S0171-2985(16)30100-0. doi: 10.1016/j.imbio.2016.06.013. [PubMed]

​

27. Mastellos D.C., Ricklin D, Hajishengallis E, Hajishengallis G, Lambris JD. Complement therapeutics in inflammatory diseases: promising drug candidates for C3-targeted intervention. Mol Oral Microbiol.  2016, 31(1):3-17. doi: 10.1111/omi.12129. [PubMed]